Skip to content
Peptigraph home

Orforglipron

Oral small-molecule GLP-1 agonist. Orforglipron is FDA approved (Foundayo, Apr 2026); research-chemical versions are not the approved drug.

Also called:Foundayoorfo
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusFDA approved (Foundayo, Apr 2026)Not on the WADA Prohibited ListFull legal history

Key facts

How we verify
Class
Oral small-molecule GLP-1 agonist
Not a peptide
Also called
Foundayo, orfo
Half-life
approximately 29 to 49 hours
oral, in people · FDA label (Foundayo)
FDA status
Approved (Foundayo, Apr 2026)
1 Apr 2026
WADA
Not listed
2026 Prohibited List
Everything on Orforglipron

Orforglipron guides

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.For weight lossWhat research says about Orforglipron for weight loss.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Orforglipron: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight loss5509Human RCT evidence, 4 of 4Lancet 2026, PMID 41275875

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Compared with

OrforglipronvsTirzepatideOral small-molecule GLP-1 agonist next to GLP-1 / GIP dual agonist: evidence, dosing and legal status side by side.FDA approved (Mounjaro, Zepbound)Read the comparison →OrforglipronvsSemaglutideOral small-molecule GLP-1 agonist next to GLP-1 agonist: evidence, dosing and legal status side by side.FDA approved (Ozempic, Wegovy, Rybelsus)Read the comparison →OrforglipronvsRetatrutideOral small-molecule GLP-1 agonist next to GLP-1 / GIP / glucagon triple agonist: evidence, dosing and legal status side by side.Investigational · phase 3Read the comparison →

Common questions

Is Orforglipron FDA approved?

Orforglipron is FDA approved (Foundayo, Apr 2026). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

Is Orforglipron a peptide?

No. It is a oral small-molecule glp-1 agonist. It is listed here because people research it alongside peptides.

Sources

  1. 1FDA approves first new molecular entity under National Priority Voucher program (Foundayo, orforglipron), 1 Apr 2026U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  3. 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  4. 4United States: Approved by FDA as Foundayo (orforglipron), Eli Lilly, 1 April 2026, for chronic weight management in adults (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  5. 5Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
  6. 6These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  7. 7Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026

Found an error? Report a correction.